All News
@RheumNow interview at #ACR24 with Dr Harry Hurley about A#1694
Should we do one or two lungs when transplanting for autoimmune related ILD?
https://t.co/2omSSAPvgi https://t.co/BlAQjuBRFt
Links:
Eric Dein ericdeinmd ( View Tweet)
Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR
Links:
Richard Conway RichardPAConway ( View Tweet)
How Online Searches Reveal Patient Needs
In the digital age, managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. #ACR24
https://t.co/AbHGNAsIpH https://t.co/nuoQeigJfE
Dr. John Cush RheumNow ( View Tweet)
A#2363
Deodhar
Bimekizumab fast time to work:
BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose.
@RheumNow #ACR24 https://t.co/T81Lzyoy7m
Eric Dein ericdeinmd ( View Tweet)
Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3
Links:
Richard Conway RichardPAConway ( View Tweet)
Disease specific chatbots might be primetime - investigators from NYC made the a #LupusCoach chatbot - patients indicated high levels of satisfaction and were excited about it.
@rheumnow abst#2160 #ACR24
Bella Mehta bella_mehta ( View Tweet)
In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Phase 2b , placebo control, double blind study
Abst #L08 #ACR24 @RheumNow https://t.co/j4qkj1Xvbr
Bella Mehta bella_mehta ( View Tweet)
Reproductive Issues in axSpA: Fertility and Pregnancy
axSpA affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their… https://t.co/8tLFOvFqdO https://t.co/E3AOOCHTgu
Dr. John Cush RheumNow ( View Tweet)
Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retention. But if they maintain treatment, appear to respond equally well. BMI no effect. @RheumNow #ACR24 Abstr#2350 https://t.co/XVPmEBbRu8 https://t.co/QyJirWRKvq
Links:
Richard Conway RichardPAConway ( View Tweet)
A#2291
ESSDAI does not correlate to PROMISE (pt outcomes) in Sjogrens
Symptomatology is complex in SjD and beyond traditional disease activity markers
@RheumNow #ACR24 https://t.co/AhstAFjOVS
Eric Dein ericdeinmd ( View Tweet)
Abstract 1873: The impact of urbanization on lupus nephritis mortality is complex.
Race/ethnicity + income modify the effects
- Income ≥$50k + living in suburbs associated with lower odds of mortality due to LN in racial/ethnic minorities
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract 1925: Caution w/ ADI as proxy for neighborhood disadvantage
- ↑ ADI didn’t correlate with ER visits or hospitalizations, but ↓ Childhood Opportunity Index (COI) did:
ER visits: aOR 2.85 (95%CI 1.12-7.26)
Hospitalizations: aOR 4.15 (95%CI 1.25-13.81)
@RheumNow #ACR24 https://t.co/dVZi8oqBnI
Akhil Sood MD AkhilSoodMD ( View Tweet)
Harkins @DrTrishHarkins et al. Impact of AC joint OA in PMR. 67% of PMR have AC joint OA. Those who do have worse pain and fatigue scores. @RheumNow #ACR24 Abstr#1974 https://t.co/vAqVuQ5Jzm https://t.co/zx5MMtWdBE
Links:
Richard Conway RichardPAConway ( View Tweet)
US biosimilar exp
Interchangeable biosimilar - can substitute for reference product wo consulting MD
Primary endpt: pharmacokinetic data
61 approved biosimilars
@RheumKay: “pts should share in financial benefits”
Currently 5-87% discount
#PBMReform @ACRheumDC
@RheumNow #ACR24 https://t.co/RqwbZalZko
Links:
Eric Dein ericdeinmd ( View Tweet)
In their cohort, Dr. Abarza et al reported a small percentage of pts developing PsA before Pso (8.6%)
This group also had faster radiographic progression vs. the Pso before PsA group.....something to consider when evaluating these pts.
@rheumnow #ACR24 abs2328 https://t.co/YPcAaKFS2I
sheila RHEUMarampa ( View Tweet)
Quote of the day. “Time is kidney” Maria Dall’Era MD, UCSF at the ACR SLE guidelines for management of lupus nephritis @RheumNow #ACR24 https://t.co/rz9AhPS2cl
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
A study investigating weight trends in Psoriatic Arthritis (PsA) and the impact of various medications. Analyzing 1754 patients, it explored multifactorial influences on weight changes
Key findings:
- Significant weight loss after starting IL17i, IL23i, and csDMARDs.
- TNFi &… https://t.co/qOl2ojV9rL https://t.co/Eh2ZNLeKhn
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#2286🔬Certolizumab Pegol (CZP) in High RF RA
📊Pooled analysis;N=1180
💥PBO: High RF=more radiographic progression v low RF (Wk24 6.5 v 2.8%,Wk52 17.6 v 10.4%)
💥CZP: min. progression regardless of RF (Wk24 0 v 1.1%;Wk52 5.3 v 3.1%)
#ACR24 @RheumNow https://t.co/koel7SDsUb
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Triboulet et al. JAKi in RA-ILD. 42 patients. Stability of PFTs over median 21 months. HRCT stable in 62%. Progressive ILD on HRCT in 19%. @RheumNow #ACR24 Abstr#2249 https://t.co/PY9BrCfNHc https://t.co/r8fIgrjyDu
Links:
Richard Conway RichardPAConway ( View Tweet)
Tesser et al. Implanted cervical vagus nerve stimulator for b/tsDMARD-IR RA. 242 patients. ACR20 week 12 35% vs 24%. Higher rates of DAS28-CRP LDA/remission. @RheumNow #ACR24 Abstr#L10 https://t.co/OXojHEMkKQ https://t.co/XSt97u7LrR
Links:
Richard Conway RichardPAConway ( View Tweet)